By Staff
Thursday, September 5, 2024 12:18 AM
VANCOUVER, British Columbia—
Kits Eyecare Ltd., a vertically integrated eyecare provider, has announced an upward revision to the company's Q3 2024 revenue guidance. The company said it now expects Q3 revenue to exceed the previously guided range of $39 million to $41 million.
By Staff
Tuesday, September 3, 2024 12:18 AM
MELBOURNE, Australia and PRINCETON, N.J.—
Opthea Limited, a clinical-stage biopharmaceutical company developing therapies to treat progressive retinal diseases, including wet age-related macular degeneration, has announced financial results for the 12 months ended June 30, 2024.
By Staff
Friday, August 30, 2024 12:24 AM
HAMBURG, Germany—Global eyewear provider
The Fielmann Group (ETR: FIE), whose network in the U.S. includes the brands SVS Vision, Befitting and the recently
acquired Shopko Optical, has announced financial results for the first six months of 2024, noting an increase in sales, revenue and profit compared with the previous year, in line with expectations. Group sales grew by 11 percent to €1,081 million in the first half of the year (previous year: €971 million), including 5 percent attributed to organic growth and 6 percent attributed to acquisition in the U.S. Eyewear sales increased by 3 percent to a total of 4.5 million pairs of glasses in the period January to June 2024 (previous year: 4.4 million pairs of glasses).
By Staff
Thursday, August 29, 2024 12:24 AM
SAN RAMON, Calif.—
CooperCompanies (Nasdaq: COO), a leading global medical device company which operates through two business units, CooperVision and CooperSurgical, has announced financial results for its fiscal third quarter ended July 31, 2024. The company reported that revenue increased 8 percent year-over-year to $1,002.8 million. CooperVision (CVI) revenue was up 7 percent to $675.6 million, and CooperSurgical (CSI) revenue grew 9 percent to $327.2 million during the quarter. The company also raised its fiscal year 2024 financial guidance.
By Staff
Wednesday, August 28, 2024 12:18 AM
ZUG, Switzerland—
Oculis Holding AG, a global biopharmaceutical company driven to improve eyecare, has announced results for the quarter ended June 30, 2024. The company reported a net loss of $23.0 million for the second quarter.
By Staff
Tuesday, August 27, 2024 12:15 AM
NEW YORK—
Eyenovia, Inc., a commercial-stage company that develops topical ophthalmic therapies, has announced the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40.
By Staff
Thursday, August 22, 2024 12:24 AM
GENEVA—
Alcon (SIX/NYSE:ALC), a global eyecare company with a portfolio of both surgical and vision care products, has announced its financial results for the three- and six-month periods ending June 30, 2024. For the second quarter of 2024, sales were reported at $2.5 billion, an increase of 3 percent on a reported basis and 6 percent on a constant currency basis, as compared with the same quarter of the previous year. Sales for the first half of 2024 were $4.9 billion, an increase of 4 percent on a reported basis and 7 percent on a constant currency basis, compared with the first half of 2023, the announcement said.
By Staff
Monday, August 19, 2024 12:15 AM
FARMINGTON HILLS, Mich.—
Ocuphire Pharma, Inc. has announced financial results for the second quarter ended June 30, 2024. Reported license and collaborations revenue was $1.1 million for the three months ended June 30, 2024.
By Staff
Friday, August 16, 2024 12:15 AM
SHANGHAI—
OcuMension Therapeutics, a leading Chinese ophthalmic pharmaceutical platform company, has announced an agreement with
Alcon Inc., a leader in eyecare, in which OcuMension has acquired commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops.
By Staff
Thursday, August 15, 2024 12:24 AM
EMERYVILLE, Calif.—
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company developing products for the eyecare market, has announced financial results for the three and six months ended June 30, 2024. Total revenue for the second quarter of 2024 was $2.4 million compared with $3.5 million in the second quarter last year. Net sales for the second quarter of 2024 were derived predominantly from sale of eyecare products, the company said, which increased 8 percent over the prior year due to more Avenova-branded products sold through online channels.
By Staff
Wednesday, August 14, 2024 12:24 AM
MIAMI, Fla.—
Innovative Eyewear Inc., (NASDAQ: LUCYW), the developer of ChatGPT-enabled smart eyewear under the Lucyd, Nautica, Eddie Bauer and Reebok brands, has announced its financial results for the second quarter of 2024. For the time period ending June 30, 2024, net revenue for the second quarter was $308,682, a reported increase of 82 percent from the same time period last year, and net revenue for the first half of the year was $692,153, an increase of 120 percent compared with the same period in 2023.
By Staff
Wednesday, August 14, 2024 12:21 AM
NEW YORK—
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced financial and operating results for the second quarter ending June 30, 2024, showing a net loss of approximately $11.1 million as compared with a net loss of $6.2 million for the second quarter of 2023.
By Staff
Tuesday, August 13, 2024 12:24 AM
NEW YORK—Eyewear company
Modo has announced the acquisition of
ICU Eyewear, a designer of over-the-counter, non-prescription reading glasses, sunglasses, blue light blocking eyewear, sun readers and outdoor specialty sunglasses, effective immediately. The strategic purchase, Modo told
VMAIL, is aimed at expanding the company's reach in reading glasses and sunwear and increasing its offerings to meet the growing demands of customers seeking readers. Modo Eyewear launched ONE:1, a sustainable carbon-negative readers brand, for the independent channel in 2023, and, according to the company, adding ICU Eyewear to this offering will allow for broader solutions.
By Staff
Monday, August 12, 2024 12:18 AM
IRVINE, Calif.—
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, announced financial results for the second quarter and year-to-date period ended June 30, 2024.
By Staff
Friday, August 9, 2024 12:27 AM
NEW YORK—
Warby Parker Inc. (NYSE: WRBY) has announced financial results for the second quarter ended June 30, 2024. The company reported that net revenue increased $22.1 million, or 13.3 percent, to $188.2 million, as compared with the prior year period. Gross profit increased 16.3 percent to $105.4 million during the second quarter, while the company reported active customers increased 4.5 percent to 2.39 million, with average revenue per customer increasing 8.8 percent to $302.